Chinese CRO WuXi PharmaTech is on board to help Genomics England pore over samples in its massive project to sequence the genomes of 100,000 Britons.
Charles River Laboratories, on the heels of some M&A-driven revenue growth, acquired another early-stage research company, paying $36 million for a German provider of drug discovery services.
Parexel International, in the midst of sweeping cost cuts, said it has further integrated technology into its drug development services, creating a data-informed process designed to speed up timelines and save money.
PRA Health Sciences is moving into a bigger space in Singapore, consolidating its operations there and looking to boost its share of the growing market for clinical research in Asia.
Quintiles has contributed some open-source code to improve Apple's ResearchKit project, a platform designed to help physicians and scientists gather medical data from millions of patients.
PPD hired a general manager to help grow its Japan-focused joint venture with Shin Nippon Biomedical Laboratories, snagging a Parexel International veteran as it works to expand its presence in a growing market for clinical development services.
Eli Lilly is partnering with CRO WuXi PharmaTech to develop a cholesterol-lowering pill in China, relying on local expertise in hopes of tapping a growing market.
BioDuro, once a division of PDD, has merged with contract manufacturer Formex, expanding its production capabilities in the U.S. while maintaining its research presence in China.
Quintiles founder Dennis Gillings is set to vacate his chairmanship at the end of 2015, ending a 33-year tenure at the top that saw the North Carolina company grow into the world's biggest CRO.
German contract researcher Evotec grew its revenue by 50% in the first 9 months of 2015, executing its hybrid model and expanding its list of Big Pharma partners.
CRO Accelovance is pairing up with a nonprofit clinical research outfit to bring its services to the developing world.
CRO giant Icon is looking to expand its share of the drug development market in Asia, hiring a pair of local veterans to deepen its ties to the region.
Catalent ticked up its year-over-year revenue in the company's fiscal first quarter, absorbing a significant hit from foreign exchange fluctuations and setting the pace for a nearly $2 billion year.
PRA Health Sciences posted another quarter of revenue growth but is narrowing its full-year sales projection.
Charles River Laboratories returned to revenue growth on a wave of dealmaking, lifting its full-year guidance in response.
Chinese CRO WuXi PharmaTech extended its run of quarterly growth on the eve of a shareholder vote that could take the company private in a multibillion-dollar deal.
Lux Ventures and a joint venture between Novartis and Qualcomm are investing $6.5 million into Science 37, an upstart company that promises to make clinical trials more efficient by uniting stakeholders.
Parexel International, in the process of shedding about 850 jobs, saw its net income dip in the fiscal first quarter, dimming its expectations for the full year.
INC Research is ticking up its revenue expectations for 2015 after turning in another quarter of sales growth, counting on its expanded operation to keep contracts rolling in.
Irish-headquartered CRO Icon kept its streak of quarterly revenue growth running, posting a 1.8% year-over-year increase in sales.